Study of YK012 in B-cell Acute Lymphoblastic Leukemia

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YK012 administered as monotherapy in participants with B-cell acute lymphoblastic leukemia (B-ALL).

Trial Details

NCT ID
NCT06580301
Phase
PHASE1 / PHASE2
Sponsor
Excyte Biopharma Ltd
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • YK012
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Guiyang, Guizhou, China|26.58333,106.71667
  • Zhengzhou, Henan, China|34.75778,113.64861

Key Eligibility Criteria

  • Participants or their legally acceptable representative must sign an ICF indicating that the participants understand the purpose of, and procedures…
  • Eastern Cooperative Oncology Group Performance Status (ECOG) of 0-2.
  • An estimated survival time of more than 12 weeks.
  • A definitive diagnosis of CD19-positive B-cell acute lymphoblastic leukemia with any of the following conditions:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →